Topics
Glioblastoma | Treatment | Immunotherapy | Nivolumab (Anti-programmed cell death protein 1)
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Nivolumab
2024
*Hendriksen JD, Locallo A, Maarup S, Debnath O, Ishaque N,
Hasselbach B, Skjøth-Rasmussen J, Yde CW, Poulsen HS,
Lassen U, Weischenfeldt J.
Immunotherapy
drives mesenchymal tumour cell state shift and TME immune response
in glioblastoma patients.
Neuro
Oncol. 2024 May 2:noae085. doi:
10.1093/neuonc/noae085. PMID:
38695342. Observational study˰
ˍ
2025
Alan O, Bulbul MC, Enlice MA, Mandel NM.
Immunotherapy-related
secondary hemophagocytosis in a glioblastoma patient: response to
cytokine-directed therapy.
Immunotherapy.
2025 Jan 15:1-7. doi:
10.1080/1750743X.2025.2451604. PMID:
39812468. Case report˰
ˍ
Neuro-Oncology Clinical Research Program; Camphausen K.
Phase
II Trial Evaluating the Association of Peripheral Blood
Immunologic Response to Therapeutic Response After Adjuvant
Treatment with Immune Checkpoint Inhibition (ICI) in Patients with
Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv
[Preprint]. 2025 Dec 30:2025.12.23.25342908. doi:
10.64898/2025.12.23.25342908. PMID:
41607658. Trial
registration ID: NCT04817254. ˍ
2026
Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M,
Bommi P, Dixit K, Kumthekar P, Sharp L, Lezon R, Garcia D,
Sonabend AM, McCortney K, Castro BA, Chandler JP, Gondi V, Grimm
SA, Miska JM, Heimberger AB, Dobinda K, Zhang H, Sachdev S, Juhasz
C, James CD, Allen JM, Horbinski C, Lesniak MS, Stupp R,
Wainwright DA.
Phase 1 evaluation of
patients with newly diagnosed glioblastoma treated with radiation,
nivolumab, and IDO1 enzyme inhibitor BMS-986205.
Clin
Cancer Res. 2026 May 26. doi:
10.1158/1078-0432.CCR-26-1124. PMID:
42189896. Trial
registration ID: NCT04047706.
ˍ
Lim M, Ye X, Piotrowski AF, Desai A, Ahluwalia MS, Walbert T,
Lesser G, Ellingson BM, Peereboom DM, Fisher JD, Desideri S,
Jackson C, Pant A, Jain A, Verma R, Oberlton B, Piyadasa H,
Bettegowda C, Engle L, Taube J, Bendall SC, Choi J, Drappatz J,
Lieberman FS, Kleinberg LR, Pardoll DM, Nabors LB, Wen PY,
Grossman SA.
Anti-LAG-3 with or
without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Nat
Med. 2026 Jul 10;32(7):2449-2460. doi:
10.1038/s41591-026-04475-7. PMID:
42432293. Trial
registration ID: NCT02658981. ˍ
Aman RA, Wayne TMLS, Hamdilah F, Adriantama MW.
Impact
of PD-1 inhibitor immunotherapy on survival in patients with newly
diagnosed and recurrent glioblastoma: a systematic review of
comparative evidence.
Folia
Med (Plovdiv). 2026 Aug 13;68(4). doi:
10.3897/folmed.68.e184377. PMID:
42677757. ˍ
Sun L, Markus LF, Sanchez JC, Lai TJ, Lee EQ, Li G, Kim J, Zhuang
Z, Acevedo B, Everson RG, Mellinghoff IK, Aquilanti E, Nicolas
Gonzalez Castro L, Ricardo McFaline-Figueroa J, Nayak L, Beroukhim
R, Chong RA, Stone J, Kaley T, Schaff L, Wilcox J, Westergaard C,
Russ A, Lavallee M, Chukwueke U, Van den Abbeele AD, Lim M,
Ellingson BM, Reardon DA, Cloughesy TF, Prins RM, Wen PY.
Neoadjuvant PD1 plus CTLA-4 immune
checkpoint blockade in surgically resectable recurrent
glioblastoma: a randomized surgical window-of-opportunity trial.
Nat
Commun. 2026 Sep 5;17(1):10560. doi:
10.1038/s41467-026-77433-z. PMID:
42838943. Trial
registration ID: NCT04606316. ˍ